Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study

BACKGROUND: GSK2190915 is a high affinity 5-lipoxygenase-activating protein inhibitor being developed for the treatment of asthma. The objective of this study was to evaluate GSK2190915 efficacy, dose–response and safety in subjects with persistent asthma treated with short-acting beta2-agonists (SA...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Follows, Richard MA, Snowise, Neil G, Ho, Shu-Yen, Ambery, Claire L, Smart, Kevin, McQuade, Barbara A
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2013
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3732081/
https://ncbi.nlm.nih.gov/pubmed/23682661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1465-9921-14-54
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires